Alzheimer's & Dementia
A 2020 meta-analysis found THC-based drugs reduced agitation in dementia — the clearest signal yet — but the evidence quality is low.
Neurology Emerging
What the research says
Agitation is one of the hardest symptoms of dementia to manage — antipsychotics carry serious risks in the elderly — which makes the cannabis signal meaningful. A 2020 systematic review and meta-analysis pooled 9 trials (205 participants, 85% with Alzheimer's disease) and found synthetic cannabinoids (dronabinol, nabilone, THC) significantly reduced agitation: about a 0.80-point improvement on the Cohen-Mansfield Agitation Inventory and 0.61 on the NPI versus placebo.
The limits matter: trials were small, short (most 2–8 weeks), and quality was rated low. There is no evidence for any effect on memory, cognition, or disease progression, and trials of depression and night-time agitation were mixed. Cannabinoids can also cause sedation, falls, and confusion in the elderly — side effects that overlap with the very symptoms being treated.
The honest caveats
The agitation signal is real enough to justify specialist-guided trials of pharmaceutical THC products (dronabinol, nabilone) in challenging dementia — and in some countries that is already done. But this is emphatically not a 'pick a strain' situation: elderly patients are fragile, drug interactions are common, and THC's cognitive and fall risks are the same symptoms families are trying to relieve. Always run this through a geriatrician or memory specialist.
Compounds to explore
These are the compounds — terpenes and cannabinoids — that the research connects to this condition. They are starting points for reading a COA or choosing a product, not prescriptions. Each has its own guide with more detail.
Cannabinoid THC Dronabinol, nabilone, and THC are the products in the agitation trials. Cannabinoid CBD Studied mostly alongside THC; no clear benefit alone in most trials.